CFRX - ContraFect Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.2985
-0.0015 (-0.50%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.3000
Open0.2919
Bid0.0000 x 900
Ask0.0000 x 1300
Day's Range0.2919 - 0.3000
52 Week Range0.2690 - 2.6290
Volume198,885
Avg. Volume292,101
Market Cap23.712M
Beta (3Y Monthly)0.17
PE Ratio (TTM)6.94
EPS (TTM)0.0430
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.13
  • GlobeNewswire

    ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., Nov. 12, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • GlobeNewswire

    ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

    ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

  • CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19...
    Zacks Small Cap Research

    CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19...

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA the company is planning to conduct a single Phase 3 clinical trial of exebacase in patients with Staphylococcus aureus bacteremia, including

  • GlobeNewswire

    ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced its plan to initiate a single Phase 3 clinical trial of exebacase for the treatment of patients with Staphylococcus aureus bacteremia, including right-sided endocarditis, following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). ContraFect has obtained concurrence with the FDA on key design features of the Phase 3 protocol, including the Day 14 primary efficacy endpoint for MRSA bacteremia, including right-sided endocarditis, and that positive results from this single Phase 3 study could support a Biologics License Application (BLA) for approval of exebacase.

  • GlobeNewswire

    ContraFect to Host Development Update Call and Webcast on October 2, 2019

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that management will host a conference call and live webcast on October 2, 2019 at 8:30 a.m. ET to discuss its plans for the development of exebacase for the treatment of patients with Staphylococcus aureus bacteremia, including endocarditis, following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

  • GlobeNewswire

    ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

    YONKERS, N.Y., Sept. 26, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • GlobeNewswire

    ContraFect to Present at the 2019 Janney Healthcare Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as a new modality for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, MD, Chairman and Chief Executive Officer, will present at the 2019 Janney Montgomery Scott Healthcare Conference on Tuesday, September 10, 2019, at 9:05 a.m. ET in New York City. The focus will be on exebacase (CF-301), the Company's novel therapeutic candidate for Staph aureus bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets. A live webcast of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

  • GlobeNewswire

    ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as a new modality for the treatment of life-threatening, antibiotic-resistant infections, today announced the company’s poster presentation of results from an ex vivo study of its amurin peptide candidate, Aap2-M1, at the jointly sponsored American Society of Microbiology and European Society of Clinical Microbiology and Infectious Disease (ASM/ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, to be held from September 3-6, 2019, in Boston. In this study, a clinically relevant concentration of Aap2-M1 eradicated Stenotrophomonas biofilms formed inside hemodialysis catheters removed from patients with suspected catheter-related bloodstream infections in the clinical care setting.

  • Zacks Small Cap Research

    CFRX: Ready to Meet with the FDA Regarding Phase 3 Plan for Exebacase…

    ContraFect Corp. (CFRX) is developing exebacase (CF-301) as the company’s lead lysin product. The company previously reported positive results from a Phase 2 clinical trial of exebacase in patients with bacteremia caused by Staphylococcus aureus, including those with endocarditis. The company has submitted all required documentation to the FDA ahead of the upcoming ‘End-of-Phase 2’ meeting, at which time the company hopes to gain agreement with the agency on the design for a Phase 3 clinical trial.

  • GlobeNewswire

    ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., Aug. 09, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • PR Newswire

    X-Biotix Therapeutics Joins Antimicrobials Working Group

    WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

    64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • Investors Who Bought ContraFect (NASDAQ:CFRX) Shares Three Years Ago Are Now Down 84%
    Simply Wall St.

    Investors Who Bought ContraFect (NASDAQ:CFRX) Shares Three Years Ago Are Now Down 84%

    As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...

  • GlobeNewswire

    ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data

    YONKERS, N.Y., June 17, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for.

  • PR Newswire

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • GlobeNewswire

    ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that the Congressionally Directed Medical Research Programs (CDMRP) has awarded the Company $7.2 million in funding from the Military Infectious Diseases Research Program (MIDRP), United States Army Medical Research and Development Command (USAMRDC) over the course of three years to advance its lysin candidate, CF-296, through IND-enabling studies after which it may enter the clinic. CF-296 was discovered while the Company was working on its platform of direct lytic agents (DLAs). Lysins, a new class of DLAs, are antimicrobial biologics with a novel mechanism of action which results in the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics.

  • GlobeNewswire

    ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development at ContraFect, will present at the invitation of the International Society of Cardiovascular Infectious Diseases (ISCVID) Symposium on Monday, June 3, 2019, in Lausanne, Switzerland. Dr. Cassino will discuss ContraFect’s lead phage-derived lysin candidate, exebacase, and promising data on the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, including endocarditis, from the Company’s Phase 2 clinical trial.

  • GlobeNewswire

    ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that an article titled “Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus” will be published in the June edition of the peer-reviewed Antimicrobial Agents and Chemotherapy Journal of  the American Society of Microbiology. Exebacase (CF-301) is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of blood stream infections (BSIs) also known as bacteremia.

  • Zacks Small Cap Research

    CFRX: R&D Symposium Highlights Positive Data for Exebacase…

    On May 14, 2019, ContraFect Corp. (CFRX) held an R&D symposium on the potential for direct lytic agents (lysins and amurins) as anti-infective agents. Included in the symposium were four presentations, including a discussion of the Phase 2 clinical trial of exebacase in patients with bacteremia caused by both methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant S. aureus (MRSA).

  • Associated Press

    ContraFect: 1Q Earnings Snapshot

    The Yonkers, New York-based company said it had profit of 15 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire

    ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., May 10, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,.

  • GlobeNewswire

    ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that it will host an R&D Symposium with widely recognized infectious disease clinicians  on the broad potential of direct lytic agents as anti-infectives, with a focus on the methicillin-resistant Staphylococcus aureus (MRSA) data  from the Phase 2 trial of exebacase, on Tuesday, May 14, 2019, at 8:30 a.m. EDT in New York. A live webcast of the event will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

  • Zacks Small Cap Research

    CFRX: Additional Phase 2 Data Presented at ECCMID…

    The data was presented by Vance G. Fowler, Jr., M.D., Professor of Medicine in the Division of Infectious Diseases at Duke University. The Phase 2 trial was an international, multicenter, randomized, double blind, placebo controlled trial with a superiority comparison between exebacase or placebo combined with the standard of care antibiotics.

  • GlobeNewswire

    ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    YONKERS, N.Y., April 16, 2019 (GLOBE NEWSWIRE) --  ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that new data from its Phase 2 clinical trial of exebacase for the treatment of Staphylococcus aureus (Staph aureus) bacteremia including endocarditis was presented by Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The oral presentation, titled “Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics Alone In A First-in-Patient Phase 2 study,” reported new data demonstrating clinically meaningful increases in clinical responder rates in the pre-specified MRSA subgroup treated with exebacase, including a 22.9% higher responder rate at Day 7 and a 16.9% higher responder rate at Test of Cure, compared to MRSA patients treated with standard of care antibiotics (SOC) alone.

  • Benzinga

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...